A Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the Treatment of Parkinson’s Disease Motor Features

Overview

The objective of this study is to test the efficacy and safety of unilateral subthalamotomy performed using the ExAblate System for the treatment of Parkinson's disease (PD) motor features.

Full Title of Study: “A Prospective, Randomized, Sham Controlled Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the Treatment of Parkinson’s Disease Motor Features”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 31, 2019

Detailed Description

A Prospective, Randomized, Sham Controlled Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the treatment of Parkinson's disease motor features.

The objective of this prospective, randomized, double-blind (to subjects, examining neurologists and external video-based examination by Movement Disorders neurologist), two-arm study (ExAblate treated arm Vs ExAblate Sham treated control arm) is to confirm the efficacy of ExAblate Model 4000 Type 1 System for the treatment of Parkinson's disease (PD) motor features and to further demonstrate safety.

Interventions

  • Device: Exablate Subthalamotomy
    • ExAblate Subthalomotomy for the Treatment of Parkinson’s Disease Motor Features
  • Device: Sham Exablate Subthalamotomy
    • Sham ExAblate Subthalomotomy for the Treatment of Parkinson’s Disease Motor Features

Arms, Groups and Cohorts

  • Experimental: Exablate Subthalamotomy
    • Exablate treatment for Parkinson’s Disease Motor Features
  • Sham Comparator: Sham ExAblate Subthalamotomy

Clinical Trial Outcome Measures

Primary Measures

  • Efficacy – MDS-UPDRS
    • Time Frame: Baseline to 4 months post treatment
    • between-group differences in the mean change (from baseline to 4 months) in the motor MDS-UPDRS score for the side contralateral to subthalamotomy (in the treated group) as compared with mean change in the MDS-UPDRS score for the side contralateral to the alleged subthalamotomy (in the sham-procedure group) in the off-medication condition
  • Safety – Adverse Events
    • Time Frame: Baseline to 4 Months post treatment
    • To evaluate the incidence and severity of adverse events (AE/AEs) associated with ExAblate subthalamotomy for the treatment of PD motor features.

Secondary Measures

  • MDS-UPDRS
    • Time Frame: Baseline to Month 4 post treatment
    • Mean change in the motor MDS-UPDRS score for the treated/allegedly treated body side in the on-medication condition (when applicable). – Mean change in specific PD motor features (i.e, tremor, rigidity and akinesia according to MDS-UPDRS III subscores in the contralateral body side). – Mean change in the motor MDS-UPDRS. MDS-UPDRS II. – Mean change in the motor MDS-UPDRS score for the treated/allegedly treated body side off-medication in a video-based examination by an external and blinded Movement Disorders neurologist. – Achievement of minimal clinical relevant reduction of the MDS-UPDRS III (as according to the literature) for the treated body side in the “treatment arm” at 4 months (intragroup Baseline to 4-months comparison) in the off-medication condition.
  • MDS-UPDRS
    • Time Frame: Baseline to Month 12 post treatment
    • Durability of the reduction in the contralateral motor MDS-UPDRS at 12 months in the treated group could also be considered.
  • UPDRS IV
    • Time Frame: Baseline to Month 12 post treatment
  • Quality of life assessment with the PDQ39
    • Time Frame: Baseline to Month 12 post treatment
  • Levodopa equivalent medication change usage (milligrams)
    • Time Frame: Baseline to Month 12 post treatment
  • Patient global impression of change
    • Time Frame: Baseline to Month 4 post treatment

Participating in This Clinical Trial

Inclusion Criteria

1. Men and women age 30 years or older

2. Subjects who are able and willing to give consent and able to attend all study visits.

3. Subjects with a diagnosis of PD by UK Brain Bank Criteria as confirmed by a movement disorder neurologist at the site.

4. Predominant motor features/disability from one side of the body (i.e asymmetry index > 1.5) as determined by a movement disorders neurologist.

5. Motor clinical features non-optimally controlled by an adequate medical treatment prescription. An adequate medication prescription is defined as a therapeutic dose of each medication or the development of side effects as the medication dose is titrated.

6. No major changes in pharmacological regime for PD should be done for the 30 days prior to procedure.

7. Topographic coordinates of the subthalamic nucleus are localizable on MRI so that it can be targeted by the ExAblate device.

8. Able to communicate sensations during the ExAblate MRgFUS treatment Inclusion and exclusion criteria have been agreed upon by two members of the medical team

Exclusion Criteria

1. Hoehn and Yahr stage in the ON medication state of 2.5 or greater

2. Presence of severe dyskinesia as noted by a score of 3 or 4 on questions 4.1 and 4.2 of the MDS-UPDRS.

3. Presence of other central neurodegenerative disease suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer's disease.

4. Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications.

5. Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia

6. Presence of significant cognitive impairment defined as score ≤ 21 on the Montreal Cognitive Assessment (MoCA) or Mattis Dementia Rating Scale of 120 or lower.

7. Unstable psychiatric disease, defined as active uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation. Subjects with stable, chronic anxiety or depressive disorders may be included provided their medications have been stable for at least 60 days prior to study entry and if deemed appropriately managed by the site neuropsychologist

8. Subjects with significant depression as determined following a comprehensive assessment by a neuropsychologist. Significant depression is being defined quantitatively as a score of greater than 14 on the Beck Depression Inventory.

9. Legal incapacity or limited legal capacity as determined by the neuropsychologist

10. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-IV as manifested by one

11. Subjects with unstable cardiac status including

12. Severe hypertension (diastolic BP > 100 on medication).

13. History of or current medical condition resulting in abnormal bleeding and/or coagulopathy.

14. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure

15. Subjects with risk factors for intraoperative or postoperative bleeding as indicated by: platelet count less than 100,000 per cubic millimeter, a documented clinical coagulopathy, or INR coagulation studies exceeding the institution's laboratory standard

16. Patient with severely impaired renal function with estimated glomerular filtration rate <30mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who is on dialysis;

17. Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.

18. Significant claustrophobia that cannot be managed with mild medication.

19. Subject who weight more than the upper weight limit of the MR table and who cannot fit into the MR scanner

20. Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment.

21. History of intracranial hemorrhage

22. History of multiple strokes, or a stroke within past 6 months

23. Subjects with a history of seizures within the past year

24. Subjects with malignant brain tumors

25. Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment.

26. Any illness that in the investigator's opinion preclude participation in this study.

27. Subjects unable to communicate with the investigator and staff.

28. Pregnancy or lactation.

29. Subjects who have an Overall Skull Density Ratio lower than 0.35 as calculated from the screening CT.

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • InSightec
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Brian Ostrander, 214.630.2000, briano@insightec.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.